Novartis ADR had its Relative Strength (RS) Rating upgraded from 78 to 82 Friday.
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
History reveals that the best stocks typically have an 80 or higher RS Rating in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
Novartis ADR is still within a buy range after climbing above a 112.98 entry in a cup with handle. The proper buying range extends to 5% above the initial entry. Once a stock moves above that range, it's best to wait for it to set up another buying opportunity.
Earnings grew 29% last quarter, up from 18% in the prior report. Revenue also increased, from 9% to 15%.
The company holds the No. 1 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health and Jazz Pharmaceuticals are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
